When therapeutic failure is observed in patients receiving lenvatinib, FGFR4 expression is presumed to exist, thus HCC may have acquired resistance to VEGF signal suppression at the time of lenvatinib failure. The gene discussed is FGFR4; the disease is hepatocellular carcinoma.